Abstract 4360927: Flow Matters: Prognostic Value of Sex-Specific Transvalvular Flow Rate in PLFLG Aortic Stenosis
Background: Paradoxical low-flow, low-gradient (PLFLG) severe aortic stenosis (AS) is a high-risk phenotype characterized by low transvalvular gradients despite preserved left ventricular ejection fraction (LVEF). While stroke volume index is conventionally used to define flow state, transvalvular flow rate (Q)—a measure incorporating both volume and ejection duration— offers a more physiologic assessment of forward flow. Given known sex-based differences in flow dynamics, we aimed to evaluate whether sex-specific Q thresholds are associated with adverse outcomes in PLFLG severe AS. Methods: We included 1,189 patients with adjudicated PLFLG severe AS (aortic valve area <1.0 cm2, mean gradient <40 mmHg, LVEF ≥50%, and Q ≤210 mL/sec) from an institutional echocardiographic database. Sex-specific Q thresholds were derived using the maximally selected rank statistic (≤150 mL/sec in males, ≤180 mL/sec in females). The primary outcome was a composite of all-cause mortality and aortic valve replacement (SAVR/TAVR). Results: In both sexes, lower Q was associated with a smaller aortic valve area, lower stroke volume index and reduced transvalvular gradients. Patients with low Q had significantly lower event-free survival, particularly among females, for both all-cause mortality and the composite outcome (log-rank p<0.001)(Figure). In a multivariable analysis, low Q independently predicted adverse composite outcome in both males (HR 1.54, 95% CI: 1.10–2.16) and females (HR 1.39, 95% CI: 1.16–1.65). Conclusion: Sex-specific transvalvular flow rate thresholds are independently associated with adverse outcomes in paradoxical low-flow low-gradient severe aortic stenosis. These findings support the clinical utility of sex-specific Q, particularly in women, for refining risk stratification and guiding timely intervention.
Authors
- Robert A. Levine (ORCID: https://orcid.org/0000-0002-9484-8218)
- Evin Yucel (ORCID: https://orcid.org/0000-0002-7074-6380)
- Jacob P. Dal‐Bianco (ORCID: https://orcid.org/0000-0001-6401-3001)
- Rachel Goldberg (ORCID: https://orcid.org/0000-0002-7072-8932)
- Jonathan Passeri (ORCID: https://orcid.org/0000-0003-2465-2460)
- Giselle Alexandra Suero‐Abreu (ORCID: https://orcid.org/0000-0002-4274-2761)
- Shani Dahan (ORCID: https://orcid.org/0000-0003-4536-9701)
- Judy Hung (ORCID: https://orcid.org/0000-0003-3737-7584)
- C. Cabrera (ORCID: https://orcid.org/0000-0002-8441-4782)
Institutions
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Circulation
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1161/circ.152.suppl_3.4360927
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00